Literature DB >> 25752107

[Eustachian tube balloon dilation in eustachian tube dysfunction related diseases].

Maojin Liang, Yiqing Zheng, Zhigang Zhang, Yaodong Xu, Yongkang Qu, Suijun Chen, Haidi Yang, Qiuhong Haung, Zeheng Qiu, Ling Chen.   

Abstract

OBJECTIVE: To investigate the effect of Eustachian tube balloon dilation (ETBD) in treatment of eustachian tube related diseases.
METHOD: Fifteen cases (20 ears) of otitis media with effusion and 22 cases (30 ears) of symptomatic Eustachian tube dysfunction were recruited. Technique of tubomanometry (TMM) showed obstructive Eustachian tube dysfunction in all patients. All the patients were received ETBD and followed up with VAS evaluation of ear fullness, muffled hearing, poping sound in the ear and tinnitus. And also the TMM change and middle ear effusion. RESULT: Ear fullness, muffled hearing released with 1 week (ear fullness: 8.2 ± 1.4 vs. 2.0 ± 1.2, P < 0.05, muffled hearing: 6.2 ± 1.2 vs. 3.1 ± 0.8, P < 0.05). No recurrence was seemed within 6 months. The eustachian function test turned better. Symptomatic Eustachian tube dysfunction had an effective rate of 96.6% while otitis media with effusion was 95.0%.
CONCLUSION: ETBD have good short-term effect in obstructive eustachian tube dysfunction related middle ear dysfunction, which might provide a good way to solve the eustachian tube related diseases.

Entities:  

Mesh:

Year:  2014        PMID: 25752107

Source DB:  PubMed          Journal:  Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi        ISSN: 1001-1781


  2 in total

1.  Diagnostic accuracy of tubomanometry R value in detecting the Eustachian tube pressure equalizing function.

Authors:  Cuneyt M Alper; Miriam S Teixeira; Jeehong H Kim; J Douglas Swarts
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-12-21       Impact factor: 2.503

2.  Clinical Analysis of Ear Congestion after Balloon Eustachian Tuboplasty (BET) with or without Tympanostomy Tube Insertion.

Authors:  Nina Chen; Shuguang Han; Wenjuan Li; Dong Li; Libo Hu; Shusheng Gong
Journal:  Evid Based Complement Alternat Med       Date:  2022-07-22       Impact factor: 2.650

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.